42.60
-0.54 (-1.25%)
| Previous Close | 43.14 |
| Open | 41.80 |
| Volume | 1,669,141 |
| Avg. Volume (3M) | 2,378,813 |
| Market Cap | 5,328,152,064 |
| Price / Sales | 8.47 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -74.02% |
| Operating Margin (TTM) | -61.10% |
| Diluted EPS (TTM) | -4.28 |
| Quarterly Revenue Growth (YOY) | 33.90% |
| Current Ratio (MRQ) | 6.22 |
| Operating Cash Flow (TTM) | -254.07 M |
| Levered Free Cash Flow (TTM) | -254.42 M |
| Return on Assets (TTM) | -16.08% |
| Return on Equity (TTM) | -609.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.74% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Barclays, 40.85%) | Buy |
| 60.00 (Canaccord Genuity, 40.85%) | Buy | |
| Median | 55.00 (29.11%) | |
| Low | 50.00 (Piper Sandler, 17.37%) | Buy |
| Average | 55.27 (29.74%) | |
| Total | 11 Buy | |
| Avg. Price @ Call | 43.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 26 Mar 2025 | 55.00 (29.11%) | Buy | 45.84 |
| Morgan Stanley | 06 Mar 2025 | 52.00 (22.07%) | Buy | 40.17 |
| Piper Sandler | 26 Feb 2025 | 50.00 (17.37%) | Buy | 43.19 |
| Canaccord Genuity | 24 Feb 2025 | 60.00 (40.85%) | Buy | 42.44 |
| Guggenheim | 24 Feb 2025 | 56.00 (31.46%) | Buy | 42.44 |
| Scotiabank | 24 Feb 2025 | 52.00 (22.07%) | Buy | 42.44 |
| Goldman Sachs | 21 Feb 2025 | 56.00 (31.46%) | Buy | 42.87 |
| 28 Jan 2025 | 49.00 (15.02%) | Buy | 48.26 | |
| JP Morgan | 21 Feb 2025 | 55.00 (29.11%) | Buy | 42.87 |
| Raymond James | 21 Feb 2025 | 59.00 (38.50%) | Buy | 42.87 |
| Stifel | 21 Feb 2025 | 53.00 (24.41%) | Buy | 42.87 |
| Barclays | 23 Jan 2025 | 60.00 (40.85%) | Buy | 48.60 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |